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Abstract
Purpose of Review For patients with chronic phase chronic myeloid leukemia (CP-CML), there is an increasing focus on
personalization of therapy with dose modifications of tyrosine kinase inhibitors (TKIs) to reduce side effects and maintain
efficacy. Dose reductions are also being considered in clinical trials prior to treatment-free remission (TFR) attempts.
Recent Findings Recent retrospective analyses of large clinical trials show that dose modification/reduction is safe. Efficacy is
generally maintained and side effects are improved. Clinical trials such as DESTINY have demonstrated that dose reduction is
safe for patients in deep molecular remission and may be considered prior to a TFR attempt.
Summary Dose modifications are widely used to prevent and manage the toxicities of TKIs. With adequate monitoring, dose
optimization is safe, reduces side effects, and improves quality-of-life for patients. Clinical trials of dose optimization are
currently recruiting across all approved TKIs and will lead to further personalization of therapy for CP-CML patients in the
future.
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Introduction
The introduction of the tyrosine kinase inhibitors (TKI) ima-
tinib, dasatinib, nilotinib, bosutinib, and ponatinib has revolu-
tionized the treatment of chronic myeloid leukemia (CML).
The vast majority of patients with CML (> 85%) are diag-
nosed in chronic phase (CP); however, if untreated, CP-
CML will progress through an accelerated phase to a fatal
acute leukemia, termed blast crisis, within 5–7 years.
Recent clinical trial data from the German CML IV study
confirm that in excess of 80% of CP-CML patients are expect-
ed to be alive after 10 years of TKI therapy, with a 10-year
relative survival of 92% compared to the general population
[1]. Many of these patients will have near normal life expec-
tancy with no progression to advanced phase disease. A recent
study from the Swedish Cancer Registry showed that patients
diagnosed in 2013 lose, on average, three life years to CML
[2]. Thus, the prevalence of CML is rapidly increasing and, in
the future, will become the most common form of leukemia
seen in the outpatient clinic. Further data from the Swedish
Cancer Registry shows that the prevalence of CML has tripled
between 1985 and 2012 from 3.9 to 11.9 per 100,000 popu-
lation, and there is a projected further increase in CML prev-
alence to 22 per 100,000 inhabitants by 2060 [3]. Similar
results were obtained in a recent French study by Delord
et al. [4]. Both studies highlight the rising economic and social
burdens of CML, with expanding costs for medication and
disease monitoring, together with the side effects of TKIs
affecting quality-of-life for patients, and potentially causing
more serious health issues. Both the economic burden and
the side effect profile of the TKIs highlight the importance
of taking a personalized approach to dose modification for
CML patients.
Monitoring Response to Therapy in CML
For patients established on a TKI, therapy is monitored using
quantitative (q)RT-PCR to measure the amount of BCR-ABL,
the causative fusion oncogene of CML [5]. QRT-PCR for BCR-
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ABL, compared to a housekeeping gene (usually ABL), accu-
rately reflects the amount of residual leukemia and, at time
points from 3 months of therapy, is used to determine whether
patients have an optimal response to TKI. This is defined as
achievement of ≦ 10% BCR-ABL:ABL transcripts at 3 months
(termed early molecular response (EMR)), [6, 7] and major
molecular response (MMR) (BCR-ABL:ABL transcripts <
0.1% on the international scale (IS)] from 12 months of TKI
therapy onwards [8]. Once MMR is achieved and maintained,
the risk of progression to advanced phase CML is extremely
low [9]. Furthermore, a proportion of patients on prolonged
TKI therapy will become persistently BCR-ABL negative, pro-
viding the tantalizing hope that TKIs may be curing some CML
patients. Indeed, trials of treatment-free remission (TFR) are
showing very encouraging results, with a proportion of optimal-
ly responding patients being able to successfully discontinue
TKI therapy (reviewed in references [10, 11]).
Are We Overtreating Optimally Responding Patients?
For optimally responding patients, we need to consider wheth-
er or not they are being overtreated with standard doses of
TKI, or indeed, if they continue to require therapy for their
CP-CML at all. This is a significant issue, as while the TKIs
and imatinib in particular have an excellent safety profile,
many patients experience persistent low-level side effects
which impact on quality-of-life [12]. In addition, there is in-
creasing evidence for more serious side effects with second
generation (2G-)TKIs which have the potential to cause sig-
nificant morbidity and mortality in some patients, for exam-
ple, pleural effusion and pulmonary arterial hypertension with
dasatinib [13]; dyslipidemia and arterial thrombotic events
with nilotinib [14, 15]; diarrhea and liver dysfunction with
bosutinib [16]; and hypertension, arterial thrombotic events,
and liver dysfunction with ponatinib [17•].
Dose modifications of TKIs in CML must have two com-
plimentary aims—the achievement and maintenance of cyto-
genetic and molecular responses, together with a reduction in
side effects. This review will discuss the evidence for dose
modifications throughout the CML patient’s treatment jour-
ney. It will consider dose modifications for newly diagnosed
patients, including the elderly, dose reduction during therapy,
often for side effects, and dose reduction for patients in deep
molecular remission (DMR) (defined as BCR-ABL:ABL ratio
of < 0.01%IS) [18], either as a prelude to an attempt at TFR or
as continuous maintenance therapy in those patients not wish-
ing to attempt TFR.
Dose Modifications in Patients with Newly Diagnosed
CP-CML
It is widely accepted that the standard starting dose of imatinib
is 400 mg/day. In clinical trials, doses above 400 mg/day have
resulted in superior efficacy, but at the expense of a worse side
effect profile, with consequent effects on quality-of-life [1,
19]. There is very limited data for starting imatinib at a dose
below 400 mg daily, unless for very elderly patients or those
with significant comorbidities and polypharmacy where side
effects and drug interactions are a concern [20•].
The Optimized Tyrosine Kinase Inhibitor Monotherapy
(OPTIM)-imatinib clinical trial was a randomized study in
patients with newly diagnosed CP-CML to consider the utility
of dose optimization based on minimal (trough) plasma con-
centrations [C]min of imatinib 2 weeks after enrolment into the
trial [21]. Those patients with a [C]min < 1000 ng/mL were
randomized to either a dose increase strategy to obtain
[C]min ≥ 1000 ng/mL on continue or 400 mg/day. Those pa-
tients with a [C]min ≥ 1000 ng/mL at the first assessment
remained on imatinib 400 mg daily. The primary endpoint
was MMR at 12 months. The MMR rate in the standard ima-
tinib arms was 37%, which improved to 63% in the dose-
optimization arm. There was no significant difference in
MMR rate between the dose-optimization arm and those with
[C]min ≥ 1000 ng/mL at the first assessment. Interestingly, on-
ly one-third of newly diagnosed CP-CML patients on imatinib
400 mg daily had [C]min ≥ 1000 ng/mL, supporting a role for
personalized treatment strategies and dose optimization for
patients commencing imatinib.
The Therapeutic Intensification in De Novo Leukemia
(TIDEL I and II) clinical trials evaluated commencing with a
starting dose of imatinib of 600 mg daily and intensifying
therapy for suboptimal response. TIDEL 1 demonstrated su-
perior responses in those patients able to tolerate 600 mg daily,
indicating that early dose intensity may be critical for optimiz-
ing response [22]. TIDEL II was a randomized study in which
all patients were commenced on imatinib 600 mg daily.
Patients with a suboptimal response from 3 months onwards
were randomized to either dose escalation to 800 mg daily
followed by switch to nilotinib for continued suboptimal re-
sponse versus switching directly to nilotinib [23]. With an
overall survival of 96% and progression-free survival of
95% at 3 years, this trial demonstrated the feasibility of initial
therapy with imatinib with an early switch to nilotinib for lack
of response.
In many clinical trials of 2G-TKIs, it was quickly discov-
ered that lower doses were as efficacious, with a better safety
profile than the maximum tolerated doses achieved in early
phase clinical trials (see Table 1). For example, the CA180-
034 study, in imatinib-resistant and intolerant patients, dem-
onstrated that 100-mg dasatinib once daily was as effective as
both 140 mg once daily or 70 mg twice daily with a more
favorable toxicity profile [24•]. This was confirmed in the
DASISION clinical trial [25] in newly diagnosed CP-CML,
where the superior efficacy to imatinib and improved safety
compared to higher doses of dasatinib used in previous trials
[30] were maintained over many years.
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A similar picture is also seen with nilotinib, where the
ENESTnd study demonstrated the equivalent efficacy of
nilotinib 300 mg and 400 mg twice daily [26], both of which
were superior to imatinib 400 mg daily. Interestingly, nilotinib
400 mg bd, but not nilotinib 300 mg bd, showed superior 5-
year overall survival compared to imatinib (P = 0.0266; ima-
tinib 91.7%, nilotinib 300 mg bd 93.7%, and 400 mg bd
96.2%). However, this was countered by a higher rate of car-
diovascular events in the nilotinib 400 mg bd arm (cardiovas-
cular events of any grade: imatinib 2.1%, nilotinib 300 mg bd
7.5%, and 400 mg bd 13.4%). Based on this, the recommend-
ed dose for newly diagnosed patients is 300 mg twice daily
and 400 mg twice daily for second-line therapy [31].
BELA, the original first-line study of bosutinib in newly
diagnosed CP-CML failed its primary endpoint of demonstrat-
ing superior cytogenetic response to imatinib, in part due to
the side effect profile of bosutinib at the recommended dose of
500 mg daily [16]. In a subsequent study (BFORE), using a
lower dose of 400 mg daily in newly diagnosed patients, su-
periority to imatinib was observed [28•], again with an im-
proved side effect profile.
In recent years, with our increased knowledge of the po-
tential of TKIs to cause significant morbidity and mortality,
together with their accepted effects in reducing quality-of-life,
there has been a renewed focus on dose modifications in an
attempt to reduce side effects, minimize treatment interrup-
tions, and obtain optimal molecular responses for patients.
As with OPTIM-imatinib, the phase 2 OPTIM-dasatinib
study used therapeutic drug monitoring (TDM) as a basis for
dose optimization [32, 33]. Patients with a high [C]min of ≥ 3/
nmol/L at the first assessment had dasatinib dose reduced by
20 mg every 2 weeks to a minimum dosage of 40 mg/day to
obtain a plasma [C]min of < 3/nmol/L. Patients randomized to
the TDM strategy had a reduced risk of pleural effusion (11%
versus 45% by 36 months, P = 0.008) and discontinuation
(13% versus 27%) compared to the control group. At
12 months, the MMR rates were equivalent between the arms.
Very recently, Naqvi et al. reported early results of a single-
arm phase 2 study exploring the efficacy and safety profile of
dasatinib 50 mg daily in newly diagnosed CP-CML [34••]. The
primary endpoint was MMR rate at 12 months. Seventy-five
patients were recruited with a median age of 47 years (range
19–84). At the time of reporting, 60 patients were evaluable for
3-month response, with 56/60 patients (93%) and 43/60 (72%)
achieving BCR-ABL:ABLIS of ≤ 10% and ≤ 1%, respectively.
Twenty-four patients had 12-months follow-up, and of these,
19/24 (79%) were in MMR, and 11/24 (71%) were in DMR.
There were no transformations to advanced phase, and only one
reported case of pleural effusion (grade 1). Nine patients had
dose interruptions of < 14 days for non-hematologic adverse
events (N = 6) or thrombocytopenia (N = 3). Although the re-
sults are very preliminary, compared to the historical
DASISION study [35], response rates at early time points are
higher in this study, and a phase 3 comparison of dasatinib
50 mg versus 100 mg may now be warranted.
Dose Modifications for Patients Established on TKI
Therapy for Management of Side Effects
The majority of TKI dose modifications are dose reductions,
instituted for the management of TKI-related side effects [20•].
There are multiple published case reports and case series of
patients reducing imatinib dose due to intolerance, and achiev-
ing and maintaining molecular response on imatinib doses be-
low the standard dose of 400 mg daily. For example, Carella
and Lerma [36] published a series of 4 patients, intolerant to
standard dose imatinib, who remained BCR-ABL negative for a
median of 17 months (range 4–37 months) on 200 mg daily.
In the Italian single-arm phase 2 INTERIM study [37], a
different approach was adopted, and Russo et al. reported
outcomes for 76 elderly patients (aged 65–83 years) treated
with an intermittent imatinib schedule (alternate months on
and off imatinib). Enrolled patients were in complete cytoge-
netic remission (CCyR) and MMR, and had been on imatinib
Table 1 Seminal dose-optimization studies of dasatinib and nilotinib
TKI Setting Doses % MMR at any time Accepted TKI dose Reference
Dasatinib
CA180-034 study
Resistance/intolerance 50 mg bd
100 mg od
70 mg bd
140 mg od
44%
46%
44%
46%
100 mg od for all chronic
phase indications
[24•]
Dasatinib
DASISION
Newly diagnosed 100 mg od versus
imatinib 400 mg od
76%
64%
[25]
Nilotinib
ENESTnd study
Newly diagnosed 300 mg bd
400 mg bd versus
imatinib 400 mg od
77%
77%
60%
300 mg bd in newly diagnosed
and 400 mg bd for
resistance/intolerance
[26]
Bosutinib
BELA
Newly diagnosed 500 mg versus
imatinib 400 mg od
59% at 24 months
49% at 24 months
400 mg od in newly diagnosed
and 500 mg od for
resistance/intolerance
[27]
Bosutinib
BFORE
Newly diagnosed 400 mg versus
imatinib 400 mg od
61.2% at 24 months
50.7% at 24 months
[28•, 29]
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for at least 2 years. With a minimum of 4 years follow-up, 27
and 13 patients had lost MMR and CCyR, respectively. All
patients losing response resumed continuous TKI therapy, and
26/27 re-achieved CCyR and MMR, with one patient lost to
follow-up. There were no progressions to advanced phase.
Dose modifications are much more common with 2G- and
3G-TKIs. In a retrospective analysis of the DASISION clinical
trial, dasatinib dose reductions did not affect efficacy, and the
superior MMR rate of dasatinib was maintained [38]. In the
NORDCML006 study [39], comparing imatinib 400 mg/day
with dasatinib 100mg/day in newly diagnosedCP-CMLpatients
(n= 46), dasatinib dose reductions for adverse events were fre-
quent; however, molecular responses were maintained. Six pa-
tients dose reduced dasatinib to a mean of 50 mg/day, and an
additional 3 patients switched from imatinib to low-dose
dasatinib. After 36 months, only 36% of patients randomized
remained on full-dose dasatinib, a further 27%were on a reduced
dose (mainly due to toxicity). However, molecular response rates
were equivalent between the standard and reduced doses.
The Japanese LD-CML study switched patients on imatinib
doses of ≤ 200 mg daily to dasatinib 50 mg daily [40]. Of the
nine patients recruited (median age 73 years, range 64–87),
eight were not in MMR. Five of eight achieved the primary
endpoint of MMR at 12 months and 3/9 achieved DMR.
There were no dasatinib dose escalations, five patients required
dose interruption, and two required dose reduction for manage-
ment of side effects. There were no transformations to advanced
phase and no treatment discontinuations for the 18-month du-
ration of the study.
The DARIA 01 study was a phase 2 study exploring factors
which influenced adherence and efficacy [41], and correlated
dasatinib [C]min on day 28 of therapy with likelihood of dose
reduction. Twenty-eight and twenty-five percent of patients,
respectively, had a dose reduction or dose interruption.
Overall, 34% of patients had their dasatinib dose reduced. In
multivariate analysis, high [C]min, older age, and poor perfor-
mance status correlated with dose reduction.
In addition to reducing from twice daily to once daily dosing
of dasatinib, an intermittent treatment schedule for dasatinib has
been reported in patients with resistance/intolerance to imatinib,
with the aim of reducing toxicity and maintaining efficacy. In a
retrospective German study, 33 patients were treated with an
“on-off” dasatinib regimen (3–5 days on therapy followed by
2–4 days off therapy) in an attempt to reduce dasatinib-related
toxicity [42]. Pleural effusions and hematological toxicity were
significantly reduced, and efficacy of this strategy was demon-
strated in 58% of evaluable patients. To more fully evaluate this
strategy of dose optimization, the Dasatinib Holiday for
Improved Tolerability (DasaHIT) clinical trial is currently ran-
domizing both newly diagnosed CP-CML patients and patients
with resistance or intolerance to alternative TKIs to dasatinib
100 mg/day continuously versus dasatinib 100 mg for 5 of
7 days (NCT02890784).
Other than the published ENESTnd clinical trial [26], there
are few studies exploring dose optimization with nilotinib. In a
single-center study, Santos et al. assessed the impact of dose
reductions and interruptions of nilotinib and dasatinib in 280
patients across all phases of CML [43]. In total, 129 patients
received nilotinib and 151 received dasatinib. Dose reductions/
interruptions were more frequent with dasatinib than nilotinib,
with 113 (75%) of patients on dasatinib and 63 (49%) patients
on nilotinib requiring a dose reduction (P < 0.0001). Using
multivariate regression analysis, older age, female sex, and
use of dasatinib were independently associated with dose mod-
ification. Importantly, there was no significant difference in
efficacy between those patients that did or did not have a dose
reduction with either nilotinib or dasatinib.
The NILO-RED observational study recruited 81 patients
to a more convenient once daily dosing regimen of nilotinib
300–450 mg [44•]. At the time of reporting, the first 67 pa-
tientswere evaluablewith aminimum follow-up of 12months.
The study included patients on both first-line nilotinib (n = 46,
300 mg twice daily) and second-line nilotinib (n = 21, 400 mg
twice daily). Two of the 46 first-line patients and none of the
second-line patients lost MMR after nilotinib dose reduction;
in these two patients, MMRwas spontaneously regained 4 and
6 months later. All patients dose reducing in DMR and 8 of 10
patients reducing in MMRmaintained response at 12 months.
In addition, a subset of these patients went on to attempt TFR.
The NILO-RED study provides preliminary evidence that a
switch to nilotinib maintenance at a once daily dose is feasible
and safe, regardless of prior therapies. Based on these results,
further prospective clinical trials are now required to more
fully evaluate nilotinib dose optimization schedules incorpo-
rating once daily dosing in optimally responding patients.
In a phase 1/2 trial of bosutinib for patients with all phases
of CML, failing two or more prior TKIs, dose reductions to
400 mg or 300 mg per day or treatment interruptions were
required in 45% and 65% of patients, respectively [45]. In
the BFORE study in newly diagnosed CP-CML patients, ad-
verse events were successfully managed with bosutinib dose
reductions to 200 mg or 300 mg daily in 103 patients [46].
Twenty of 103 patients were in MMR at time of dose reduc-
tion, and only one patient lost MMR after dose reduction. An
additional 40 patients obtained MMR after dose reduction. In
an ongoing bosutinib dose-optimization study at the MD
Anderson Cancer Center, in patients that have failed their
first-line TKI, bosutinib is being commenced at a dose of
300 mg per day, and then increased if required in an attempt
to minimize side effects and improve tolerability
(NCT02906696). These studies highlight that dose optimiza-
tion for bosutinib continues.
Moving on to consider dose optimization for the 3G-TKI
ponatinib, a phase 2 dose-finding study, OPTIC
(NCT02467270), has very recently completed recruitment to
establish the most effective dose of ponatinib together with
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minimization of side effects, in particular, arteriothrombotic
events (ATE). The approval for ponatinib at a dose of 45 mg
daily was based on the PACE clinical trial, published in 2013
which demonstrated the efficacy of ponatinib in patients with
resistance and intolerance to multiple TKIs across all phases
of disease, including those with T315I mutations [47].
However, longer follow-up of PACE identified a high and
increasing rate of ATE in patients treated with ponatinib which
raised significant safety concerns [17•], led to immediate dose
reductions to 15 mg in responding patients, the abandonment
of the first-line EPIC clinical trial comparing ponatinib 45 mg
daily with imatinib [48], and led to an FDA black box warning
for ponatinib. Modeling the data from PACE suggested that
there was a dose-effect relationship for both response and side
effects. Thus, lowering the dose may reduce cardiovascular
toxicity but maintain efficacy. This hypothesis is being tested
in OPTIC to determine the optimal starting dose of ponatinib.
Patients with resistance to at least two other TKIs are being
randomized between doses of 15-mg, 30-mg, and 45-mg
ponatinib. On achievement of major cytogenetic remission
(MCyR) or BCR-ABL:ABLIS ratio ≤ 1%, the dose is reduced
to 15 mg for all patients. The primary endpoint is MCyR by
12 months.
Some clinical trials, e.g., the German CML IV Study, have
assessed doses of imatinib higher than the standard 400mg daily
to improve efficacy [1]. Of 422 patients randomized to the high-
dose imatinib arm in the CML IV study, 68 reduced to imatinib
400 mg daily after achieving MMR [49]. Sixty-one of 68
remained in MMR after dose reduction, 5/68 transiently lost
MMR, but regained this while continuing on imatinib 400 mg
daily. Only 2/68 patients (3%) switched to a more potent TKI to
regain MMR. These results demonstrate that reductions in treat-
ment intensity for patients on high-dose imatinib (reduction from
800mg to 400mg) in patients inMMRare feasible and safe with
the vast majority of patients maintaining MMR.
The information presented above provides evidence that
dose reduction/interruption is safe and feasible. It has no
effect on overall survival and minimal effects on molecular
and cytogenetic responses. Importantly, dose reduction/
interruption does improve side effect profiles and is a suit-
able method for managing many adverse events. However,
it is unclear whether these strategies should be adopted
more widely and not just for management of adverse
events. Further prospective studies are required to evaluate
this and also determine if there is a minimum effective dose
of TKIs which should be considered prior to switching to
an alternative TKI.
Consideration of Dose Reduction for Patients in DMR
For optimally responding patients, TKI dose reduction may be
considered for the management and prevention of adverse
events, leading to improved quality-of-life. However, to date,
these have been very limited prospective evaluation of this
approach. There are two potential scenarios: (1) patients con-
tinuing long term on a reduced dose of TKI as “maintenance
therapy” with a resultant improvement in tolerability and (2)
patients reducing TKI dose prior to a TFR attempt.
In a small study, 43 patients in DMR on imatinib 400 mg
daily for a median of 4.1 years had a dose reduction to 300 mg
daily [50]. With a median follow-up of 1.6 years on imatinib
300 mg daily, only 2/43 patients had lost DMR, but main-
tained MMR, not patients lost MMR. Improvements in side
effects were observed in 23/37 patients that reported side ef-
fects at the time of dose reduction.
The UK De-Escalation and Stopping Therapy with
Imatinib, Nilotinib or sprYcel (DESTINY) [51••] clinical trial
set out to explore the two potential scenarios above, prospec-
tively. In addition, for the first time, DESTINY explored the
feasibility and safety of dose reduction and treatment cessa-
tion in patients in stable MMR, and not necessarily in DMR.
One hundred seventy-four patients who had been on TKI
therapy for at least 3 years and in stable MMR (n = 49) or
DMR (n = 125) for at least 12 months were recruited.
Patients with prior documented resistance were excluded.
Enrolled patients received 50% standard dose of TKI (IM
200 mg daily (n = 148), nilotinib 200 mg twice daily (n =
16), and dasatinib 50 mg daily (n = 8)) for the first 12 months,
with monthly molecular monitoring. Patients maintaining
MMR then attempted TFR and were followed for a further
24months. During the 12months of TKI reduction, molecular
recurrence (defined as loss ofMMR) occurred in 3/121 (2.5%)
and 9/48 (18.8%) evaluable patients in the DMR and MMR
groups, respectively. The recurrence rate was significantly
lower in the DMR group (P = 0.0007). Importantly, all pa-
tients regained MMR within 4 months of restarting full-dose
TKI. Interestingly, all recurrences on half-dose therapy oc-
curred on imatinib and not a 2G-TKI, which may be a reflec-
tion of the higher potency of the 2G-TKIs. During the first
3 months of dose reduction, there was a significant improve-
ment in side effects. In addition, there were substantial finan-
cial savings made from the TKI drug budget.
The UK DESTINY trial demonstrates that dose reduction
is safe and feasible for patients in DMR. It is associated with
the maintenance of molecular response in the vast majority of
patients, especially if DMR has been achieved and main-
tained, as well as significant improvements in side effects
and cost savings.
In the second phase of the DESTINY trial [52•], TFR after
dose reduction was attempted for all patients remaining in
MMR after 12 months of dose reduction. After a further
24 months of monitoring in TFR, the recurrence-free survival
rate (defined as maintenance of MMR) was 72% in the DMR
group and 36% in the MMR group. The only factor predictive
of recurrence was treatment duration, and there was no asso-
ciation between recurrence and age, gender, performance
Curr Hematol Malig Rep (2019) 14:337–345 341
status, or prior therapies. There were 2 non-CML-related
deaths and no progressions to advanced phase. All episodes
of molecular recurrence re-achieved MMR within 5 months.
Again, there was a further improvement in symptom burden
during the first few months of TFR. The period of dose reduc-
tion did not prevent symptoms of the TKI withdrawal syn-
drome which occurred in 21% of patients [53].
The excellent successful TFR rate of 72% in the DESTINY
DMR group raises the controversial question as to whether dose
reduction prior to stopping in some way improves the outcome.
The TFR rate in the DESTINY DMR group is substantially
better than that of the much bigger EUROSKI clinical trial
[54•], which at 2 years had a recurrence-free survival rate of
50%; both studies had almost identical inclusion criteria. The
potential mechanisms behind this are unclear, but effects on
CML stem cells, the immune system and improved compliance
during the dose-reduction phase may all contribute. Further stud-
ies are now warranted to define the optimal dose-reduction strat-
egies, not only for patients wishing to continue on long-term
reduced dose TKI maintenance, but also for patients in DMR
considering TFR. While dose reduction for side effects for pa-
tients inMMR is safe and feasible, provided adequatemonitoring
is available, TFR attempts should be reserved for those patients
in DMR, except in exceptional circumstances.
Table 2 Current and ongoing TKI dose-optimization/modification clinical trials in CML list on the www.clinicaltrials.gov website (Accessed on
February 28, 2019)
Trial title TKI(s) Patient population Primary endpoint NCT number
Effect of pharmacogenetics on imatinib
plasma level and response
Imatinib CML on imatinib for
at least 12 months
(n = 100)
MMR NCT03262974
Gleevec as maintenance therapy after
cytogenetic response with nilotinib
in newly diagnosed chronic myelogenous
leukemia
Nilotinib
Imatinib
Newly diagnosed CP-CML
(n = 25)
Maintenance of CCyR
on imatinib after nilotinib
induction
NCT01316250
The efficacy and safety of induction-
maintenance protocol for patients
with chronic myelogenous leukemia
Dasatinib
Nilotinib
Imatinib
Newly diagnosed CP-CML
(n = 15)
Maintenance of molecular
progression-free survival
NCT03241199
Optimization of TKIs treatment and quality-
of-life in Ph + CML patients ≥ 60 years in
deep molecular response
Dasatinib
Nilotinib
Imatinib
CP-CML aged ≥ 60
in MMR/MR4.0
(n = 502)
Changes in quality-of-life NCT02326311
KISS study: Kinase Inhibition with
Sprycel Start (KISS)
Dasatinib
Imatinib
Newly diagnosed CP-CML
(n = 100)
Maintenance of MMR 2 years after
switch to imatinib
NCT03193281
Low-dose dasatinib as first-line treatment
for chronic myeloid leukemia
Dasatinib Newly diagnosed CP-CML
(n = 12)
Molecular response
at 6 months
NCT03216070
Low-dose dasatinib (50 mg daily) as
first-line treatment for newly diagnosed
chronic phase chronic myeloid leukemia
Dasatinib Newly diagnosed CP-CML
(n = 100)
MMR at 12 months NCT03625388
Dasatinib Holiday for Improved Tolerability
(DasaHIT)
Dasatinib Newly diagnosed CP-CML
and resistance/intolerance
to first-line TKI in CP-CML
(n = 306)
Cumulative toxicity score and MMR NCT02890784
Phase II study testing the tolerability of
bosutinib in chronic phase CML patients
(BODO)
Bosutinib Resistance/intolerance to
first-line TKI in CP-CML
(n = 127)
Rate of GI-toxicity within
the first 6 months of
treatment
NCT03205267
Bosutinib dose-optimization study in
chronic myeloid leukemia (CML)
Bosutinib Resistance/intolerance to
first-line TKI in CP-CML
(n = 42)
Rate of MCyR NCT02906696
Bosutinib in Elderly Chronic Myeloid
Leukemia (BEST)
Bosutinib Resistance/intolerance to
first-line TKI in CP-CML
(n = 65)
Rate of MMR at 12 months NCT02810990
Activity and risk profile of ponatinib in
chronic phase patients with chronic
myeloid leukemia resistant to imatinib
Ponatinib Second-line after failure of
first-line imatinib therapy
(n = 78)
Rate of MCyR at 12 months NCT02398825
Ponatinib in participants with resistant
chronic phase chronic myeloid
leukemia (CP-CML)
to characterize the efficacy and safety of a
range of doses (OPTIC)
Ponatinib CP-CML with failure of at least
two prior TKIs
(n = 276)
Rate of BCR-ABL:ABL
ratio of ≤ 1% at 12 months
NCT02467270
CCyR, complete cytogenetic response; CP-CML, chronic phase chronic myeloid leukemia;MCyR, major cytogenetic response;MMR, major molecular
remission; MR4.0, molecular remission 4.0
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Conclusions and Future Directions
Over many years, multiple clinical trials across all TKIs have
demonstrated the importance of dose optimization via dose
modifications. The two main goals of this approach are to
maintain the excellent efficacy of TKIs while reducing side
effects. Side effects may be persistent and low grade, such as
the chronic fatigue and fluid retention associated with imatin-
ib, where persistence over many years impacts quality-of-life,
more serious such as pleural effusion associated with
dasatinib, or life threatening, e.g., the increased ATEs seen
with nilotinib and ponatinib.
Dose modifications may be considered at all stages of the
patient’s treatment journey. Evidence is accruing that dose
modifications are safe and feasible throughout treatment and
are an important consideration for the prevention and manage-
ment of side effects, improving adherence and reducing treat-
ment interruptions. Dose modifications may be particularly
useful in the elderly or those with multiple comorbidities.
A list of currently recruiting dose-optimization/modifica-
tion studies is shown in Table 2. Novel, prospective clinical
trials are required to explore dose optimization in CP-CML,
from newly diagnosed patients through those experiencing
resistance or intolerance to those wishing to attempt TFR.
These important studies will lead to further improvements in
quality-of-life and outcome for CP-CML patients.
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